Pay in 4 interest-free payments of $6.68 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Most patients experience constipation during the first 2-4 weeks as their digestive system adapts, with symptoms improving as the body acclimates to the medication
In a 48-week Phase 2 obesity trial, participants on the 12mg dose recorded a mean body-weight reduction of 24.2%, versus 2.1% on placebo[1]. 83% of that group lost 15% or more of their body weight, and 93% lost at least 10%[1]
If a patient is on an ARB, the healthcare provider should closely monitor electrolyte levels and kidney function
The medication is administered as a once-weekly injection, with guidance provided on injection techniques to ensure optimal efficacy
is supported by the BMBF via EkoEstMedFKZ 01ZZ2015
US$ 20.16
US$ 27.82
US$ 25.71
US$ 25.85
